« Return to News | Drug Sponsors

Valeant moves global headquarters to Quebec

Wednesday, April 4, 2012 01:48 PM

Valeant Pharmaceuticals International is moving its global headquarters to the Montreal region and establishing an R&D center of excellence for consumer dermatology in nearby Laval, Quebec.

With support from the Quebec government, Valeant hopes to set a precedent by becoming the first and only multinational pharmaceutical company to have its global headquarters in Quebec.

"Valeant has always had a strong Canadian presence and with our operations continuing to perform well, we expect to continue to increase our activities here in Canada," stated J. Michael Pearson, chairman and CEO, Valeant. 

In addition to having its head office in the Montreal region, Valeant will have other important assets in the province of Quebec, with Laboratoire Dr Renaud and a newly acquired manufacturing facility being critical components of the company's emerging position as a leader in the dermatology sector.

Pearson added, “The Montreal region [will be] a strategic development center for our consumer dermatology product division.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.